Brokerages Set UiPath Inc. (NASDAQ:PATH) Price Target at $50.07

Shares of UiPath Inc. (NASDAQ:PATHGet Rating) have been assigned a consensus recommendation of “Hold” from the twenty-six research firms that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and twelve have given a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $50.07.

A number of brokerages have recently issued reports on PATH. Macquarie raised shares of UiPath from a “neutral” rating to an “outperform” rating in a research report on Tuesday, January 25th. Needham & Company LLC cut their price objective on shares of UiPath from $85.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, March 31st. Credit Suisse Group lowered their target price on shares of UiPath from $75.00 to $57.50 and set an “outperform” rating on the stock in a report on Thursday, March 31st. Wells Fargo & Company cut their price target on UiPath from $45.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, March 31st. Finally, Evercore ISI lowered their price objective on UiPath from $57.00 to $36.00 in a research note on Tuesday, March 29th.

In other UiPath news, Director Kimberly Hammonds sold 2,521 shares of the company’s stock in a transaction that occurred on Friday, March 18th. The shares were sold at an average price of $28.19, for a total value of $71,066.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rich Wong sold 75,000 shares of UiPath stock in a transaction on Friday, February 18th. The stock was sold at an average price of $37.81, for a total transaction of $2,835,750.00. The disclosure for this sale can be found here. Insiders have sold a total of 152,521 shares of company stock worth $5,729,067 in the last 90 days.

Institutional investors have recently bought and sold shares of the stock. ARK Investment Management LLC increased its position in shares of UiPath by 12.4% during the fourth quarter. ARK Investment Management LLC now owns 26,902,940 shares of the healthcare company’s stock worth $1,160,324,000 after buying an additional 2,969,072 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its position in UiPath by 24.8% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 17,615,356 shares of the healthcare company’s stock valued at $759,750,000 after acquiring an additional 3,500,987 shares during the last quarter. Nikko Asset Management Americas Inc. boosted its position in UiPath by 17.2% during the fourth quarter. Nikko Asset Management Americas Inc. now owns 16,513,378 shares of the healthcare company’s stock valued at $718,662,000 after acquiring an additional 2,419,307 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in UiPath by 72.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 6,437,445 shares of the healthcare company’s stock worth $277,647,000 after acquiring an additional 2,697,742 shares during the period. Finally, BlackRock Inc. raised its position in shares of UiPath by 40.7% in the 4th quarter. BlackRock Inc. now owns 5,217,393 shares of the healthcare company’s stock worth $225,025,000 after acquiring an additional 1,510,056 shares in the last quarter. 51.80% of the stock is currently owned by institutional investors.

UiPath stock opened at $19.04 on Friday. UiPath has a twelve month low of $18.90 and a twelve month high of $90.00. The company’s 50-day moving average price is $29.23 and its two-hundred day moving average price is $39.94.

UiPath (NASDAQ:PATHGet Rating) last released its quarterly earnings results on Wednesday, March 30th. The healthcare company reported $0.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.02. UiPath had a negative return on equity of 21.20% and a negative net margin of 58.91%. The business had revenue of $289.70 million during the quarter, compared to analysts’ expectations of $283.25 million. The firm’s revenue was up 39.3% on a year-over-year basis. As a group, equities analysts forecast that UiPath will post -0.46 earnings per share for the current fiscal year.

About UiPath (Get Rating)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

Further Reading

Analyst Recommendations for UiPath (NASDAQ:PATH)

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.